Boston Scientific Corporation (BSX) is a global medical device company with a market cap of $138.8 billion, providing innovative technologies for various medical conditions worldwide. Despite underperforming the market in the past year, BSX stock rose nearly 4% on Oct. 22, 2025, following better-than-expected Q3 earnings. The company reported adjusted EPS of $0.75 and revenue of $5.07 billion, raising its 2025 EPS forecast and guiding higher for Q4. Analysts expect adjusted EPS to grow 21.1% year-over-year to $3.04, with a consensus rating of “Strong Buy” from 31 analysts. Bernstein analyst Lee Hambright maintains a “Buy” rating on BSX with a price target of $130, representing a 33.8% premium to current levels.

Read more at Barchart: Boston Scientific Stock: Analyst Estimates & Ratings